Authors
Ryan, ClodaghPrice, Vicotria
John, Philip
Mahant, Sanjay
Baruchel, Sylvain
Brandao, Leonardo
Blanchette, Victor
Pope, Elena
Weinstein, Miriam
Affiliation
Department of Haematology, Mercy University Hospital, Grenville Place, Cork,, Ireland.Issue Date
2012-01-31T16:39:23ZMeSH
Adrenal Cortex Hormones/*administration & dosageAntineoplastic Agents, Phytogenic/administration & dosage
Female
Hematologic Diseases/blood/*drug therapy/*mortality
Humans
Infant
Infant, Newborn
Interferons/administration & dosage
Male
Pentoxifylline/administration & dosage
Platelet Aggregation Inhibitors/administration & dosage
Platelet Count
Retrospective Studies
Vincristine/administration & dosage
Metadata
Show full item recordCitation
Eur J Haematol. 2010 Feb 1;84(2):97-104. Epub 2009 Nov 3.Journal
European journal of haematologyDOI
10.1111/j.1600-0609.2009.01370.xPubMed ID
19889011Abstract
OBJECTIVE: Kasabach-Merritt phenomenon (KMP) can lead to life-threatening bleeding, and its optimum treatment has not been established. We review the experience of managing KMP in a single institution. METHODS: A retrospective chart review on all children with KMP treated at the Hospital for Sick Children, Toronto, over an 18 yr period was carried out. RESULTS: All 15 patients had profound thrombocytopenia and hypofibrinogenemia at presentation, half had bleeding symptoms, and three had cardiac failure. All patients received corticosteroids. Five responded to steroids alone, given for an average of 13 wk, increasing platelets to >20 x 10(9)/L at a mean of 6.2 d and fibrinogen >1 g/dL at 25.6 d. Ten patients received at least one other therapeutic modality in addition to steroids, including vincristine, interferon, anti-platelet agents and pentoxifylline. Five patients received vincristine, for a mean of 6 wk, with two patients responding. Eight patients received interferon, for a mean of 4 months, with two patients responding. Overall, the mean time to increasing platelets >20 x 10(9)/L was 56 d, to >150 x 10(9)/L was 88 d and fibrinogen >1 g/dL 49 d. Ten patients showed a partial response to embolisation, with a mean of 2.8 procedures performed. Thrombotic complications occurred in 7%. Twelve patients remain alive, with relapse in six patients, all treated successfully. One patient died, and two patients have been lost to follow-up. CONCLUSION: KMP is a rare condition, with significant morbidity and mortality. The therapeutic approach should include a multidisciplinary team and consensus on guidelines.Language
engISSN
1600-0609 (Electronic)0902-4441 (Linking)
ae974a485f413a2113503eed53cd6c53
10.1111/j.1600-0609.2009.01370.x
Scopus Count
Collections
Related articles
- Long-term outcome of vincristine-aspirin-ticlopidine (VAT) therapy for vascular tumors associated with Kasabach-Merritt phenomenon.
- Authors: Fernandez-Pineda I, Lopez-Gutierrez JC, Chocarro G, Bernabeu-Wittel J, Ramirez-Villar GL
- Issue date: 2013 Sep
- Treatment of Corticosteroid-Resistant Vascular Tumors Associated with the Kasabach-Merritt Phenomenon in Infants: An Approach with Transcatheter Arterial Embolization Plus Vincristine Therapy.
- Authors: Tan X, Chen M, Zhang J, Zhou S, Shen G, Liu Z, Jiang H, Xia J
- Issue date: 2016 Apr
- Steroid-resistant kaposiform hemangioendothelioma: a retrospective study of 37 patients treated with vincristine and long-term follow-up.
- Authors: Wang Z, Li K, Yao W, Dong K, Xiao X, Zheng S
- Issue date: 2015 Apr
- [Introduction of laparoscopic splenectomy for the treatment of immune thrombocytopenic purpura].
- Authors: Kiudelis M, Endzinas Z, Mickevicius A, Reckauskas M
- Issue date: 2004 Apr
- Outcome of Kasabach-Merritt phenomenon: the role of vincristine as monotherapy: report of a case.
- Authors: Traivaree C, Lumkul R, Torcharus K, Krutuecho T, Sriphaisal T
- Issue date: 2012 May